Amarin (AMRN) Competitors $15.88 +0.10 (+0.63%) As of 01:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AMRN vs. MESO, EWTX, TVTX, CVAC, PAHC, ABCL, CALT, HROW, WVE, and AMPHShould you be buying Amarin stock or one of its competitors? The main competitors of Amarin include Mesoblast (MESO), Edgewise Therapeutics (EWTX), Travere Therapeutics (TVTX), CureVac (CVAC), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), Calliditas Therapeutics AB (publ) (CALT), Harrow (HROW), WAVE Life Sciences (WVE), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical products" industry. Amarin vs. Its Competitors Mesoblast Edgewise Therapeutics Travere Therapeutics CureVac Phibro Animal Health AbCellera Biologics Calliditas Therapeutics AB (publ) Harrow WAVE Life Sciences Amphastar Pharmaceuticals Mesoblast (NASDAQ:MESO) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability. Is MESO or AMRN more profitable? Mesoblast has a net margin of 0.00% compared to Amarin's net margin of -41.07%. Mesoblast's return on equity of 0.00% beat Amarin's return on equity.Company Net Margins Return on Equity Return on Assets MesoblastN/A N/A N/A Amarin -41.07%-17.21%-12.16% Does the media refer more to MESO or AMRN? In the previous week, Mesoblast had 1 more articles in the media than Amarin. MarketBeat recorded 3 mentions for Mesoblast and 2 mentions for Amarin. Mesoblast's average media sentiment score of 1.01 beat Amarin's score of 1.00 indicating that Mesoblast is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amarin 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, MESO or AMRN? Mesoblast has a beta of 2.39, indicating that its stock price is 139% more volatile than the S&P 500. Comparatively, Amarin has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Do analysts prefer MESO or AMRN? Mesoblast currently has a consensus price target of $18.00, indicating a potential upside of 60.64%. Amarin has a consensus price target of $12.00, indicating a potential downside of 24.43%. Given Mesoblast's stronger consensus rating and higher possible upside, equities research analysts plainly believe Mesoblast is more favorable than Amarin.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has preferable earnings & valuation, MESO or AMRN? Amarin has higher revenue and earnings than Mesoblast. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMesoblast$5.67M252.51-$87.96MN/AN/AAmarin$228.61M1.44-$82.18M-$3.64-4.36 Do insiders and institutionals have more ownership in MESO or AMRN? 1.4% of Mesoblast shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 2.0% of Amarin shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryMesoblast beats Amarin on 12 of the 15 factors compared between the two stocks. Get Amarin News Delivered to You Automatically Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMRN vs. The Competition Export to ExcelMetricAmarinMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$328.88M$2.92B$5.56B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-4.3620.3528.6119.64Price / Sales1.44304.32437.49188.30Price / CashN/A43.1536.0257.93Price / Book0.677.718.185.63Net Income-$82.18M-$55.11M$3.23B$257.73M7 Day Performance-8.37%0.68%-0.25%0.07%1 Month Performance14.41%8.22%5.40%8.32%1 Year Performance0.49%-2.64%26.35%13.78% Amarin Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMRNAmarin0.2846 of 5 stars$15.88+0.6%$12.00-24.4%+5.1%$328.88M$228.61M-4.36360Negative NewsMESOMesoblast2.1929 of 5 stars$10.53-1.4%$18.00+70.9%+43.3%$1.35B$5.90M0.0080EWTXEdgewise Therapeutics1.4581 of 5 stars$12.61-3.2%$40.00+217.2%-41.5%$1.33BN/A-8.1460TVTXTravere Therapeutics3.7915 of 5 stars$14.60-2.7%$32.14+120.2%+67.0%$1.30B$273.53M-5.20460Positive NewsAnalyst RevisionCVACCureVac4.7219 of 5 stars$5.41-0.7%$6.83+26.3%+50.3%$1.21B$523.70M5.88880Positive NewsPAHCPhibro Animal Health3.9916 of 5 stars$29.90+6.8%$24.40-18.4%+73.6%$1.21B$1.02B38.331,940High Trading VolumeABCLAbCellera Biologics2.2819 of 5 stars$4.03+6.1%$7.50+86.1%+23.1%$1.20B$28.83M-7.20500Analyst ForecastHigh Trading VolumeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180HROWHarrow2.3829 of 5 stars$31.36-1.2%$61.40+95.8%+38.3%$1.15B$199.61M-56.00180Analyst RevisionWVEWAVE Life Sciences4.4941 of 5 stars$7.06+1.6%$20.50+190.4%+28.7%$1.10B$108.30M-8.40240News CoverageAnalyst ForecastGap UpAMPHAmphastar Pharmaceuticals4.292 of 5 stars$22.86-1.5%$32.33+41.4%-45.4%$1.08B$731.97M8.282,028 Related Companies and Tools Related Companies Mesoblast Alternatives Edgewise Therapeutics Alternatives Travere Therapeutics Alternatives CureVac Alternatives Phibro Animal Health Alternatives AbCellera Biologics Alternatives Calliditas Therapeutics AB (publ) Alternatives Harrow Alternatives WAVE Life Sciences Alternatives Amphastar Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMRN) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Corporation PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMRN Stock Alerts